Multicomponent metaplastic breast cancer with four histological components: A case report

doi:10.12998/wjcc.126027

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 27

This Article

(3)

(2)

(0)

(36)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Clin Cases. Sep 26, 2026; 14(27): 126027
Published online Sep 26, 2026. doi: 10.12998/wjcc.126027

Table 1 Pirarubicin plus cyclophosphamide followed by docetaxel plus cisplatin

Cycle	Treatment date	Drug	Dose (mg/m²)	Actual total dose per cycle (mg)	Route	Dose adjustment	Adverse event	CTCAE 5.0 grade¹	Management	Reason for the delay
1	August 31, 2024	Pirarubicin cyclophosphamide	40; 200	62; 310	Infusion	No	-	-	-	-
2	September 27, 2024	Pirarubicin cyclophosphamide	40; 200	62; 310	Infusion	No	-	-	-	Respiratory infection
3	October 20, 2024	Pirarubicin cyclophosphamide	40; 200	62; 310	Infusion	No	Leukopenia	Grade 2	G-CSF²	Leukopenia
4	November 11, 2024	Pirarubicin cyclophosphamide	40; 200	62; 310	Infusion	No	Nausea/vomiting neutropenia alopecia	Grade 2	5-HT3 receptor antagonist³; G-CSF	-
5	December 1, 2024	Docetaxel cisplatin	75; 20 (d1-d3)	116; 93	Infusion	No	Anorexia nausea/vomiting leukopenia	Grade 2	Nutritional support; 5-HT3 receptor antagonist+Dexamethasone	-
6	December 22, 2024	Docetaxel cisplatin	75; 20 (d1-d3)	116; 93	Infusion	No	Anorexia nausea/vomiting leukopenia	Grade 2	Nutritional support; 5-HT3 receptor antagonist+Dexamethasone; G-CSF	-
7	January 13, 2025	Docetaxel cisplatin	75; 20 (d1-d3)	116; 93	Infusion	No	Anorexia nausea/vomiting leukopenia	Grade 3	Nutritional support; 5-HT3receptor antagonist+Dexamethasone	-
8	February 4, 2025	Docetaxel cisplatin	75; 20 (d1-d3)	116; 93	Infusion	No	Anorexia nausea/vomiting leukopenia	Grade 2	Nutritional support; 5-HT3receptor antagonist+Dexamethasone	-

¹CTCAE 5.0, Common Terminology Criteria for Adverse Events version 5.0.

²G-CSF, Granulocyte Colony-Stimulating Factor.

³5-HT3 receptor antagonist, 5hydroxytryptamine type 3 receptor antagonist.

Full Size Table

Citation: Zhao TJ, Chen SL, Zhou YL, Jin ZJ, Huang GS. Multicomponent metaplastic breast cancer with four histological components: A case report. World J Clin Cases 2026; 14(27): 126027
URL: https://www.wjgnet.com/2307-8960/full/v14/i27/126027.htm
DOI: https://dx.doi.org/10.12998/wjcc.126027

Zhao TJ, Chen SL, Zhou YL, Jin ZJ, Huang GS. Multicomponent metaplastic breast cancer with four histological components: A case report. World J Clin Cases 2026; 14(27): 126027 [DOI: 10.12998/wjcc.126027]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.